Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization

Reuters

08/28

Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization

Lytix Biopharma AS, a clinical-stage immuno-oncology company, has announced advancements in its clinical programs, positioning the company for a milestone-rich second half of 2025. The company is making strides in the development of Ruxotemitide (formerly LTX-315), with the program reaching significant milestones. A successful End-of-Phase II FDA meeting for basal cell carcinoma has been completed through its partner Verrica, and patient treatment in the ATLAS-IT-05 trial in advanced melanoma has concluded. Additionally, enrollment is ongoing in the NeoLIPA study for early-stage melanoma, with interim results anticipated in November 2025. The results for the second quarter and first half of 2025 were presented in a webcast by CEO Øystein Rekdal and CFO Gjest Breistein, with a recording available on the company's website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20250827:BIT:8248:0) on August 28, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2562470435"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562470435\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562470435?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-28 13:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562470435","market":"fut","top_or_hot":-1,"title":"Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lytix Biopharma AS, a clinical-stage immuno-oncology company, has announced advancements in its clinical programs, positioning the company for a milestone-rich second half of 2025. The company is making strides in the development of Ruxotemitide (formerly LTX-315), with the program reaching significant milestones. A successful End-of-Phase II FDA meeting for basal cell carcinoma has been completed through its partner Verrica, and patient treatment in the ATLAS-IT-05 trial in advanced melanoma has concluded. Additionally, enrollment is ongoing in the NeoLIPA study for early-stage melanoma, with interim results anticipated in November 2025. The results for the second quarter and first half of 2025 were presented in a webcast by CEO Øystein Rekdal and CFO Gjest Breistein, with a recording available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20250827:BIT:8248:0) on August 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-28 13:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lytix Biopharma AS, a clinical-stage immuno-oncology company, has announced advancements in its clinical programs, positioning the company for a milestone-rich second half of 2025. The company is making strides in the development of Ruxotemitide (formerly LTX-315), with the program reaching significant milestones. A successful End-of-Phase II FDA meeting for basal cell carcinoma has been completed through its partner Verrica, and patient treatment in the ATLAS-IT-05 trial in advanced melanoma has concluded. Additionally, enrollment is ongoing in the NeoLIPA study for early-stage melanoma, with interim results anticipated in November 2025. The results for the second quarter and first half of 2025 were presented in a webcast by CEO Øystein Rekdal and CFO Gjest Breistein, with a recording available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20250827:BIT:8248:0) on August 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nNDL9nX8lT:1","article_id":"2562470435","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562470435","pubTimestamp":1756357637,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization. Lytix Biopharma AS, a clinical-stage immuno-oncology company, has announced advancements in its clinical programs, positioning the company for a milestone-rich second half of 2025. The company is making strides in the development of Ruxotemitide , with the program reaching significant milestones. A successful End-of-Phase II FDA meeting for basal cell carcinoma has been completed through its partner Verrica, and patient treatment in the ATLAS-IT-05 trial in advanced melanoma has concluded. Additionally, enrollment is ongoing in the NeoLIPA study for early-stage melanoma, with interim results anticipated in November 2025. The results for the second quarter and first half of 2025 were presented in a webcast by CEO ystein Rekdal and CFO Gjest Breistein, with a recording available on the company's website.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","VRCA":"Verrica Pharmaceuticals Inc."},"translate_title":"Lytix Biopharma AS宣布2025年下半年具有里程碑意义，Ruxotemitide临床试验取得进展，并为未来商业化做好战略准备","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRCA":0.9},"content_text":"Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization\n    \n\n        Lytix Biopharma AS, a clinical-stage immuno-oncology company, has announced advancements in its clinical programs, positioning the company for a milestone-rich second half of 2025. The company is making strides in the development of Ruxotemitide (formerly LTX-315), with the program reaching significant milestones. A successful End-of-Phase II FDA meeting for basal cell carcinoma has been completed through its partner Verrica, and patient treatment in the ATLAS-IT-05 trial in advanced melanoma has concluded. Additionally, enrollment is ongoing in the NeoLIPA study for early-stage melanoma, with interim results anticipated in November 2025. The results for the second quarter and first half of 2025 were presented in a webcast by CEO Øystein Rekdal and CFO Gjest Breistein, with a recording available on the company's website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20250827:BIT:8248:0) on August 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}